Sio Capital Management LLC Purchases 1,193,024 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Sio Capital Management LLC raised its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 153.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,971,948 shares of the company’s stock after acquiring an additional 1,193,024 shares during the period. Ventyx Biosciences makes up 1.7% of Sio Capital Management LLC’s portfolio, making the stock its 18th biggest holding. Sio Capital Management LLC owned approximately 2.79% of Ventyx Biosciences worth $4,299,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of VTYX. China Universal Asset Management Co. Ltd. grew its holdings in shares of Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the period. Palumbo Wealth Management LLC acquired a new stake in Ventyx Biosciences during the third quarter worth $26,000. SG Americas Securities LLC bought a new stake in Ventyx Biosciences in the 2nd quarter valued at $32,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Ventyx Biosciences by 3.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,101 shares of the company’s stock valued at $1,058,000 after buying an additional 17,898 shares in the last quarter. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Raju Mohan purchased 261,752 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the acquisition, the chief executive officer now directly owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. The trade was a 13.68 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 18.18% of the stock is owned by insiders.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX opened at $2.65 on Friday. Ventyx Biosciences, Inc. has a 12 month low of $1.67 and a 12 month high of $11.48. The company’s 50-day moving average price is $2.20 and its two-hundred day moving average price is $2.62.

Wall Street Analysts Forecast Growth

VTYX has been the topic of several recent research reports. Canaccord Genuity Group decreased their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Wells Fargo & Company decreased their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. HC Wainwright restated a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research report on Monday, November 11th. Finally, Oppenheimer reiterated an “outperform” rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Ventyx Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.